CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath Lung Effective January 2024 Seite 1

30.11.2023 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) ... Seite 1

Related Keywords

United States ,American , ,Medicare Advisory Panel ,Precision Pathology Laboratory Services ,Medicare Clinical Lab Fee Schedule ,Medicare Advisory Panel On Clinical Diagnostic Laboratory ,Laboratory Analyses ,American Medical Association ,Clinical Diagnostic Laboratory Tests ,Current Procedural Terminology ,Clinical Lab Fee Schedule ,Cypath Lung ,Bioaffinity Technologies Aktie ,Ioaffinity Technologies Inc ,